All In MedTech

Device Trial Radar · NCT06716385

A Clinical Trial to Evaluate the Vision Correction Safety and Efficacy of MSiHy Silicone Hydrogel Soft Contact Lens

A Prospective, Randomized, Double-blind, Parallel, Active-controlled Clinical Trial to Evaluate the Vision Correction Safety and Efficacy of MSiHy Silicone Hydrogel Soft Contact Lens

Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Oct 9, 2024

Primary completion

Aug 7, 2025

Study completion Aug 7, 2025

Sponsor

Lead sponsor
Visco Vision Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 4, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, double-blind, parallel, active-controlled, multi-center clinical study. The purpose is to evaluate the safety and effectiveness wearing "MSiHy Silicone Hydrogel Soft Contact Lens". Subjects will be randomized in 1:1 ratio to wear either the investigational device "MSiHy Silicone Hydrogel Soft Contact Lens" or the control device Monthly Silicone Hydrogel Contact Lenses(oA)".

Conditions

  • Myopia
  • Refractive Errors

Interventions

  • MSiHy Silicone Hydrogel Soft Contact LensDevice

    The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.

  • Monthly Silicone Hydrogel Contact Lenses (oA)Device

    The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual CorrectionTime frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • MayKay Memorial Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.